CTC intelligence company CelLBxHealth plc (AIM: CLBX) announced on Monday that it has entered a collaboration with AdventHealth, a US-based faith-based health system, to use its Parsortix platform in two clinical studies focused on minimally invasive cancer monitoring through circulating tumour cell analysis.

ACTION and SUNRISE studies will isolate and analyse circulating tumour cells from blood samples of patients undergoing treatment for colon, gastrointestinal and lung cancers. Researchers will use the Parsortix platform to perform tumour cell enumeration and PD-L1 characterisation, providing real-time insight into tumour biology without invasive biopsies.

The NIH-funded ACTION study is enrolling 219 colon cancer patients to assess how aerobic exercise impacts chemotherapy tolerability, while the SUNRISE study, expected to begin in July 2026, will evaluate remotely delivered exercise interventions in 120 gastrointestinal and lung cancer patients.

Across both studies, circulating tumour cell analysis will serve as a clinical endpoint to help researchers monitor tumour evolution and treatment response.

CelLBxHealth said the collaboration supports a more patient-centric oncology model by combining remote interventions with blood-based diagnostics to reduce travel requirements and improve access to precision cancer care in community settings.

The company added that AdventHealth's national network of hospitals and outpatient facilities provides an opportunity to expand adoption of the Parsortix platform and broader use of liquid biopsy technologies in routine oncology care.